 We are pleased to invite investors and analysts to participate in our virtual event on Monday, 25 November 2024, showcasing how computation biology and AI/ML/LLM get integrated into early drug discovery and drug development following the “lab in a loop” concept. Speaker Aviv Regev, Head of Genentech Research and Early Development (gRED) 16:30 - 18:00 CET / 15:30 - 17:00 GMT 10:30 am - 12:00 pm EST / 7:30 - 9:00 am PST The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:30 CET on the day of the event. >click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards, |
| Bruno Eschli Head of Investor Relations | Jon Bayard Investor Relations Officer |
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
get the latest news and updates to your inbox.